
CASI Pharmaceuticals (CASI) Stock Forecast & Price Target
CASI Pharmaceuticals (CASI) Analyst Ratings
Bulls say
CASI Pharmaceuticals Inc. is anticipated to experience robust revenue growth, with projections of reaching $36 million in 2023 and increasing to $59 million in 2024, bolstered by the launch of new products and strengthening market position. The recent approval of CNCT19 for treating relapsed and refractory B-cell acute lymphoblastic leukemia positions the company favorably, as it is expected to capture significant market share due to its cost advantage and first-mover status in China. Additionally, promising results from the Phase 1 study of BI-1206 indicate strong potential for its immune-modulating therapies, further enhancing the company's growth outlook.
Bears say
CASI Pharmaceuticals Inc. is facing a negative financial outlook, primarily driven by a significant 59% year-over-year decline in revenues attributed to increased generic competition for its lead product, Evomela, in the Chinese market. The anticipated launch of CNCT19 has been delayed from the first quarter to the fourth quarter of 2024, further complicating the company's growth prospects, particularly given the lowered probability of success for this key product. Additionally, projections indicate a net loss of $1.93 per share for 2023, reflecting fundamental challenges in revenue generation and increased competition.
This aggregate rating is based on analysts' research of CASI Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
CASI Pharmaceuticals (CASI) Analyst Forecast & Price Prediction
Start investing in CASI Pharmaceuticals (CASI)
Order type
Buy in
Order amount
Est. shares
0 shares